Here is the design of a clinical trial:

Official Title: Short Course Antibiotic Treatment of Gram-negative Bacteremia: A Multicenter, Randomized, Non-blinded, Non-inferiority Interventional Study

Included conditions:
- Gram-negative Bacteremia
- Urinary Tract Infection Bacterial

Study Armgroups:
- {'label': 'Intervention group', 'type': 'EXPERIMENTAL', 'description': 'Shortened antibiotic treatment of 5 days', 'interventionNames': ['Other: Shortened antibiotic treatment']}
- {'label': 'Control group', 'type': 'ACTIVE_COMPARATOR', 'description': 'Standard antibiotic treatment of minimum 7 days at the discretion of treating physician', 'interventionNames': ['Other: Standard antibiotic treatment']}

Interventions:
- {'type': 'OTHER', 'name': 'Shortened antibiotic treatment', 'description': 'Shortened antibiotic treatment of 5 days. Participation in the study will only affect treatment duration and will have no influence on the choice of treatment in respect to type and dose of antibiotic treatment.', 'armGroupLabels': ['Intervention group']}
- {'type': 'OTHER', 'name': 'Standard antibiotic treatment', 'description': 'Standard antibiotic treatment of minimum 7 days at the discretion of treating physician. Participation in the study will only affect treatment duration and will have no influence on the choice of treatment in respect to type and dose of antibiotic treatment.', 'armGroupLabels': ['Control group']}

Primary Outcomes:
- {'measure': '90-day survival without clinical or microbiological failure to treatment', 'description': '90-day survival without clinical or microbiological failure to treatment as defined:\n\n1. All-cause mortality from day of randomization and until day 90\n2. Microbiological failure: Recurrent bacteremia due to the same microorganism as verified by sequence analysis occurring from day of randomization and until day 90\n3. Clinical failure: Re-initiation of therapy against Gram-negative bacteremia for more than 48 hours due to clinical worsening suspected to be due to the initial infecting organism and for which there is no alternate diagnosis/pathogen suspected from the day of randomization and until day 90\n\n   1. Distant complications of initial infection, defined by growth of the same bacteria as in the initial bacteremia (e.g. endocarditis, meningitis)\n   2. Local suppurative complication that was not present at infection onset (e.g. renal abscess in pyelonephritis)', 'timeFrame': '90 days'}

Please estimate the sample size based on the assumption: 
Given an α of 5% and a β of 90%, a sample size re-estimation (SSR) will be considered at the first planned interim analysis. If the overall event rate falls outside the expected event rate of 12%, an SSR based on a blinded review of overall data will be performed. The non-inferiority margin may be reduced to ensure an appropriate margin relative to the event rate. Any sample size adjustment will be reported to the regulatory authorities as a protocol amendment.
Sample size
        Based on a similar previous study, short-term mortality is expected to be approximately 12% in both treatment arms. Failure is expected to be 8% in both study arms.19 Because individuals who are not stable by day 5, who have complicated infections, who have a polymicrobial infection or infection with Pseudomonas spp, Brucella spp and Fusobacterium spp are not eligible, we anticipate these rates to be lower at 8% and 4%, respectively. This corresponds to an estimated event rate for the primary outcome of approximately 12%, equivalent to a 90-day survival without clinical or microbiological failure to treatment or relapse of 88% in both treatment arms.
        Non-inferiority is defined as an absolute risk difference or margin in the primary endpoint of up to 10%, as recommended by the European Medicines Agency.26 Given an Î± of 5% and a Î² of 90% then 362 randomised individuals are required to be sure that the lower limit of a one-sided 95% CI will exclude a difference in favour of the longer course of antibiotics of more than 10%. Allowing for a dropout rate of 5%, 380 individuals will be included.
        A sample size re-estimation (SSR) will be considered at the first planned interim analysis. If the overall event rate falls outside the expected event rate of 12%, an SSR based on a blinded review of overall data (ie, without knowledge of the group-specific event rates) will be performed. If the overall event rate is lower than expected, then the final sample size will be reduced, using the original sample size formula and replacing the initial estimate with the observed rate. The non-inferiority margin may be reduced to ensure an appropriate margin relative to the event rate. If the overall event rate is higher than expected, the sample size will be increased correspondingly. Any sample size adjustment will be reported to the regulatory authorities as a protocol amendment.